Valuation: Guerbet

Market Cap 83.89M 94.5M 78.51M 71.16M 134M 9.11B 135M 943M 367M 4.65B 355M 347M 14.94B P/E 2026 *
-3.73x
P/E 2027 * 7.24x
Enterprise Value 459M 518M 430M 390M 736M 49.9B 741M 5.16B 2.01B 25.46B 1.94B 1.9B 81.83B EV / Sales 2026 *
0.6x
EV / Sales 2027 * 0.57x
Free-Float
36.58%
Yield 2026 *
2.51%
Yield 2027 * 3.51%
1 day+6.48%
1 week-5.65%
Current month-12.09%
1 month-11.71%
3 months-26.52%
6 months-28.06%
Current year-56.17%
1 week 6.17
Extreme 6.17
7.03
1 month 6.17
Extreme 6.17
7.05
Current year 6.17
Extreme 6.17
14.92
1 year 6.17
Extreme 6.17
18
3 years 6.17
Extreme 6.17
39.4
5 years 6.17
Extreme 6.17
43.65
10 years 6.17
Extreme 6.17
89.68
Manager TitleAgeSince
Chief Executive Officer - 01/02/2026
Chief Executive Officer - 21/09/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 44 28/05/2015
Director/Board Member 50 18/05/2017
Director/Board Member 52 21/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
+6.48%-5.65% - - 94.04M
-2.06%-2.41%+21.93%+33.03% 250B
-1.81%-3.89%+2.65%+0.04% 156B
-0.25%-1.55%-9.76%+37.24% 144B
-0.55%-3.73%-56.31%-18.95% 61.45B
-0.77%-1.56%+13.25%+17.65% 50.28B
+1.66%-1.50%-21.21%-19.75% 46.73B
-0.76%-2.95%+19.95%+53.52% 48.29B
+0.40%+2.29%-4.94%+35.95% 45.89B
-0.65%-1.38%+33.44%+63.49% 43.24B
Average +0.17%-2.32%-0.11%+22.47% 93.91B
Weighted average by Cap. -1.02%-2.77%+3.43%+22.95%

Financials

2026 *2027 *
Net sales 764M 860M 715M 648M 1.22B 82.95B 1.23B 8.59B 3.34B 42.32B 3.23B 3.16B 136B 798M 899M 747M 677M 1.28B 86.68B 1.29B 8.97B 3.49B 44.22B 3.38B 3.3B 142B
Net income -35.8M -40.33M -33.5M -30.37M -57.35M -3.89B -57.76M -402M -157M -1.98B -151M -148M -6.38B 8.3M 9.35M 7.77M 7.04M 13.3M 901M 13.39M 93.29M 36.28M 460M 35.1M 34.34M 1.48B
Net Debt 376M 423M 351M 319M 602M 40.79B 606M 4.22B 1.64B 20.81B 1.59B 1.55B 66.89B 370M 417M 347M 314M 593M 40.21B 598M 4.16B 1.62B 20.51B 1.57B 1.53B 65.95B
Projected Income Statement - Annual - Guerbet
Logo Guerbet
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows: - X-ray imaging products (54.4%); - MRI products (32.1%); - other (13.5%): contrast products for echography and nuclear medicine, fine chemicals products. At the end of 2024 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil. Net sales are distributed geographically as follows: Europe/Middle East/Africa (43.8%), Americas (29.7%) and Asia (26.5%).
Employees
2,700
Date Price Change
06/10/26 €6.180 +0.16%
05/10/26 €6.170 -3.59%
02/10/26 €6.400 -3.76%
01/10/26 €6.650 -5.41%
30/09/26 €7.030 +7.33%
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Guerbet
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
6.650EUR
Average target price
8.433EUR
Spread / Average Target
+26.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Guerbet